



Published in final edited form as:

Magnetochemistry. 2021 July ; 7(7): . doi:10.3390/magnetochemistry7070092.

Enrichment and Detection of Antigen-Binding B Cells for Mass Cytometry

Zachary C. Stensland¹, Mia J. Smith^{1,2,*}

¹Barbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA;

²Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA

Abstract

Over the years, various techniques have been utilized to study the function and phenotype of antigen-binding B cells in the primary repertoire following immunization, infection, and development of autoimmunity. Due to the low frequency of antigen-reactive B cells (<0.05% of lymphocytes) in the periphery, preliminary enrichment of cells is necessary to achieve sufficient numbers for statistically sound characterization, especially when downstream analytic platform use, e.g., CyTOF, is low throughput. We previously described a method to detect and enrich antigen-reactive B cells from peripheral blood and tissues using biotinylated antigens in conjunction with magnetic nanoparticles, preparative to a downstream analysis by ELISPOT and flow cytometry. While mass cytometry (CyTOF) enables high dimensional immunophenotyping of over 40 unique parameters on a single-cell level, its low throughput compared to flow cytometry and requirement for removal of metal contaminants, such as nanoparticles, made it particularly unsuitable for studies of rare cells in a mixed population. Here we describe a novel CyTOF-compatible approach for multiplexed enrichment of antigen-reactive B cells, e.g., insulin and tetanus toxoid, using cleavable magnetic nanoparticles. This method allows improved monitoring of the phenotype and function of antigen-reactive B cells during the development of disease or after immunization while minimizing the amount of sample and run times needed.

Keywords

CyTOF; mass cytometry; magnetic enrichment; antigen-specific B cells; antigen-binding B cells; antigen-reactive B cells; B lymphocytes; B cells

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

*Correspondence: mia.smith@cuanschutz.edu.

Author Contributions: Conceptualization, M.J.S.; Writing—original draft preparation, Z.C.S., and M.J.S.; Writing—review and editing, Z.C.S. and M.J.S.; visualization, Z.C.S. and M.J.S.; supervision, M.J.S.; project administration, M.J.S.; funding acquisition, M.J.S. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the University of Colorado Anschutz Medical Campus (01–384, 12-June-2019).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

1. Introduction

Effective study of the biology of antigen-reactive B cells before and during the development of the immune responses and their perturbation during disease development requires examination of B cells on an antigen-specific level. Previous methods to identify antigen-reactive B cells have included assays such as limiting dilution, ELISPOT, and most commonly flow cytometry [1–9]. Previously, we developed a method to identify and enrich rare antigen-reactive B cells from polyclonal repertoires using biotinylated antigen and magnetic nanoparticles, which is compatible with a variety of downstream assays [10]. Using this method, we studied changes in the phenotype of self-reactive B cells during the development of type 1 diabetes and autoimmune thyroid disease, as well as foreign-reactive (e.g., tetanus) B cells prior to and after vaccination [10–14]. While our previous method has been instrumental in better understanding phenotypic changes in antigen-reactive B cells during the course of the disease and after vaccination, it is limited by the relatively low number of parameters able to be assayed simultaneously by flow cytometry (even with spectral flow cytometry).

Mass cytometry, or CyTOF (Fluidigm), is a technology that combines flow cytometry and mass spectrometry in which antibodies or other ligands used to label cells are conjugated to heavy metal isotopes that are identified using time-of-flight mass spectrometry [15,16]. Some advantages of mass cytometry over traditional fluorescence-based flow cytometry are that currently as many as 50 individual parameters can be analyzed simultaneously with minimal spillover between output signals and little need for compensation or unmixing. Like flow cytometry, mass cytometry can be used to study the phenotypic and functional properties of various cell types thanks to its compatibility with pre-existing methods such as immunophenotyping, intracellular staining, and phosphoflow. Moreover, it was recently demonstrated that mass cytometry is comparable to flow cytometry in terms of quantification of cell lineages and markers of activation, function, and exhaustion using low numbers of human PBMCs [17].

Hence, in order to take advantage of the high-parameter single-cell immunophenotyping capability of mass cytometry, we developed a method to enable enrichment and identification of antigen-binding B cells from human PBMCs that is compatible with mass cytometry. During the initial development of this method, we first attempted to identify antigen-reactive B cells using directly metal labeled antigens that bind to the B cell receptor (BCR) followed by CyTOF analysis, without intervening enrichment. However, we found that due to the low throughput of mass cytometry statistically sound characterization of antigen-reactive B cells using mass cytometry necessitates prior enrichment of the cells of interest. However, unlike flow cytometry, for this analysis, magnetic nanoparticles must be removed from enriched cells because they contain barium and other heavy metals that may foul the spectrometer. This can be accomplished using “cleavable” beads, as previously described [18]. Hence, in our method, we utilize commercially available cleavable anti-biotin and anti-FITC magnetic beads to enrich our antigen-reactive B cells of interest. In addition, after careful optimization, we have modified our previous method to enable the identification and tracking of more than one type of antigen-reactive B cell within the same sample. Importantly, while successful identification of antigen-specific T cells has been

previously shown using mass cytometry [18–20], to our knowledge, this is the first study to demonstrate the ability to characterize antigen-reactive B cells using this tool. Moreover, previous studies to analyze antigen-specific T cells using mass cytometry have either, (1) used metal labeled tetramers to detect antigen-specific T cells without prior enrichment, resulting in very few cells of interest for analysis, or (2) enriched for antigen-reactive T cells based on upregulation of activation markers (e.g., CD69) after stimulation with antigen *in vitro*. Hence, our method is unique in that it combines detection using the antigen of interest as bait with enrichment using cleavable beads, resulting in a more pure population for analysis.

Here we demonstrate simultaneous enrichment of insulin-binding B cells and tetanus-toxoid-binding B cells from the peripheral blood of healthy individuals using mass cytometry. The basic steps for our protocol are as follows: first, PBMCs are incubated with a live-dead marker [21], followed by staining with FITC conjugated tetanus-toxoid and biotinylated insulin. Cells are fixed, followed by enrichment of antigen-binding B cells using cleavable anti-biotin and anti-FITC magnetic beads and LS MACS columns (Miltenyi Biotech, Bergisch Gladbach, Germany). The magnetic beads are then cleaved away from labeled cells. After washing, the enriched cells are stained with metal-labeled antibodies to various cell surface markers, as well as metal labeled anti-FITC and anti-biotin antibodies to identify tetanus and insulin-binding B cells, respectively. Finally, enriched cells are analyzed by the mass cytometer. A schematic for this method is represented in Figure 1 and the materials needed are listed in Table 1. We conclude with a discussion of the various limitations of the method and important considerations that should be taken into account when applying the method.

2. Materials and Methods

Protocol:

1. Isolation of PBMC's from Whole Blood
 1. Collect 30–50 mL of heparinized blood collection tubes
 2. Dilute heparinized blood 1:1 with sterile, room temperature magnesium and calcium-free phosphate-buffered saline (PBS).
 3. In a 50 mL conical tube, add 10–15 mL of room temperature Ficoll-Paque PLUS.
 4. Carefully layer 30–35 mL of the diluted blood on the top of the Ficoll-Paque at the lowest speed setting, being careful not to mix the two.
 5. Centrifuge at $400\times g$ for 30 min at room temperature with the brake turned off.
 6. Using a serological pipette remove the mononuclear layer (buffy coat) and transfer to a clean 50 mL conical. Add at least 3 times the volume of PBS to the cell suspension.

7. Centrifuge cells at $400\times g$ for 10 min at room temperature with the brake on.
 8. Remove supernatant and resuspend cells in 10 mL PBS. Count cells and determine viability using a hemocytometer or automated cell counter.
 9. Adjust cell concentration to 3×10^7 cells/1 mL CSM buffer and place on ice until ready to begin processing.
2. Viability Dye
 1. Centrifuge 30×10^6 cells at $400\times g$ for 5 min at room temperature and aspirate supernatant.
 2. Wash cells $1\times$ with 1 mL sterile PBS
 - i. Do not use any solutions with serum or protein content until after cisplatin incubation.
 3. Spin down at $400\times g$ for 5 min at room temperature and aspirate supernatant.
 4. Resuspend cells in serum-free RPMI at 3×10^6 cells per 1 mL RPMI.
 5. Add 1 uL (25 mM stock) of Cisplatin per 1 mL of serum-free RPMI and vortex samples briefly to mix thoroughly (25 uM final concentration).
 6. Incubate for 1 min at RT before quenching solution with 2 mL CSM or complete RPMI per 1 mL of cisplatin-cell solution.
 - i. It is necessary to quench with a solution that contains protein to bind extraneous cisplatin
 7. Spin cells at $400\times g$ for 5 min at room temperature and aspirate supernatant.
 3. Enrichment of antigen-reactive B cells
 1. Wash cells once with 1 mL CSM. Centrifuge cells at $400\times g$ for 5 min and aspirate supernatant.
 2. Resuspend cells in 25 uL Fc Block and allow them to bind for 5 min on ice. Do not wash off.
 3. Add 1 mL CSM to cells before adding antigen(s) at their pre-determined amount. Vortex briefly to mix and incubate on ice for 15 min in the dark.
 - i. Note: Biotinylated and FITC conjugated antigens should be titrated to determine the optimal concentrations needed to ensure detection and separation of binding cells from non-specific bystander cells. Typically, a good starting concentration is between 0.025 ug and 1 ug per 1×10^6 cells. (See Smith et al. for detailed protocol [10])

the column into the depleted fraction. Repeat with another 3 mL of cold CSM.

14. Place a new 15 mL conical tube labeled “enriched” under the LS column and fill with 6 mL of cold CSM. Plunge the CSM through the column using equal steady pressure to collect cells held in the magnetic field using the provided plunger.
 15. Centrifuge both depleted and enriched fractions of cells at $400\times g$ for 10 min at 4 °C.
 16. Resuspend the depleted fraction in an appropriate volume to re-count. Resuspend $2\text{--}3 \times 10^6$ cells from the depleted fraction in 1 mL cold CSM in a 1.5 mL Eppendorf tube. Resuspend the enriched fraction in 1 mL cold CSM in a 1.5 mL Eppendorf tube (we assume the number of cells in our enriched fraction is 1 million cells).
 17. Add 20 uL multi-sort release agent per 1 mL cell suspension. Vortex briefly to mix and incubate for 10 min at 4 °C in the dark.
 18. Wash cells by adding 9–10 mL cold CSM to the cell suspension and centrifuge at $400\times g$ for 10 min at 4 °C.
 19. Aspirate supernatant and wash again in 1 mL cold CSM at $400\times g$ for 10 min at 4 °C.
 20. Partially aspirate supernatant leaving approximately 50 uL of CSM in the tube.
4. Surface Staining
1. Create 100 uL 2X antibody master mix (MM) of surface antibodies from Table 2 in CSM.
 - i. Note: The optimal amount of each metal labeled antibody to add should be determined beforehand.
 - ii. Add 2 uL each of ^{160}Gd -anti-FITC and ^{170}Er -anti-biotin antibodies to the MM to detect tetanus and insulin-reactive B cells, respectively.
 2. Add 50 uL of MM to the depleted sample and 50 uL MM to the enriched sample, such that the final concentration of antibodies per sample is 1X. Vortex briefly and incubate on ice for 15–20 min in dark.
 3. Add 1 mL CSM to samples and centrifuge at $400\times g$ for 5 min.
 4. Aspirate supernatant and resuspend in 100 uL of 1.6% PFA. Allow cells to stain in dark for 5 min. Add 1 mL CSM and centrifuge at $400\times g$ for 5 min.
 5. While spinning, create an intercalator cocktail:
 - i. 1 mL 1.6% PFA + 0.5 uL intercalator IR per sample.

6. Add 1 mL of intercalator solution to each sample and leave at 4 °C for a minimum of 20 min or up to 1 week.
7. Wash 3× in MilliQ water.
8. Resuspend in 1 mL MilliQ water per million cells for running on mass cytometer.
9. Data acquisition and analysis
10. Acquire data on mass cytometer, as previously described [21].
11. Analyze data using third-party analysis software, such as FlowJo (Treestar) or CellEngine [22].

3. Representative Results

To demonstrate the method described above, we show representative mass cytometry data obtained using FITC labeled tetanus-toxoid and biotinylated insulin as model antigens to detect and enrich simultaneously for foreign and self-reactive B cells, respectively, from the peripheral blood of a healthy individual. Figure 1 is an overall schematic of the method. Figure 2 shows a comparison of the method using flow cytometry and mass cytometry starting from ~60 million fresh PBMCs from the same donor that were divided in half and enriched as described above with fluorescently labeled markers substituted for the flow cytometry sample. The donor was last vaccinated with tetanus-toxoid more than 2 years prior to the analysis. Insulin and tetanus-binding B cells were found in frequencies similar to those observed by flow cytometry. Hence, antigen-binding cells are not differentially lost with mass cytometry. However, cell recovery was reduced with mass cytometry compared to flow cytometry, as expected. For the flow cytometry sample, there were approximately 3000 insulin-binding B cells and 2000 tetanus-binding B cells identified, and for the mass cytometry sample, there were approximately 1000 insulin-binding B cells and 500 tetanus-binding B cells identified. Despite the cell loss, antigen-binding B cells can still be easily analyzed for expression of other markers to distinguish varying B cell subpopulations and expression of cell surface markers.

Figure 3 demonstrates a representative manual gating strategy used to define major B cell subsets and analysis of cell surface expression of various markers using mass cytometry (Table 2). Figure 3A shows representative gating used to identify insulin, tetanus, and non-binding B cells. We have previously shown that the use of magnetic beads to enrich antigen-binding B cells inevitably results in a number of non-binding bystander cells that get trapped in the matrix [10]. While these impurities can be removed by FACS sorting, non-binding cells represent a good internal negative control to determine differences between non-binding and binding B cells. Figure 3B–D demonstrate representative gating to identify major B cell subjects, including naïve, memory, IgG+ memory, double-negative (DN), anergic (B_{ND}), DN2, plasmablast, and transitional B cells. Once major B cell subpopulations are identified using manual gating strategies, heat maps expressing the mean metal intensities (MMI) of various cell surface molecules can be generated to identify populations

that may be highly activated or have altered expressions of varying surface markers (Figure 3E).

One of the major advantages of mass cytometry is the large number of parameters that can be analyzed simultaneously, which allows for high dimensional reduction and unbiased monitoring of the immune system. There are many well-written reviews that discuss the various unsupervised clustering algorithms available to analyze mass cytometry data [23–25]. In Figure 4, we show an example of how the unsupervised clustering algorithm, PhenoGraph, can be used to identify various B cell subpopulations using UMAP projections and how the population makeup of insulin, tetanus, and non-binding B cells can be easily visualized and compared. Using this method, we can conclude that in this individual that insulin-binding B cells occur in almost all B cell subpopulations, but particularly in the transitional and naïve (CD27⁻) subpopulations (populations 1, 3, 4, and 6) and in the B_{ND} anergic population (population 4), while tetanus-binding B cells are enriched in the memory subpopulations (populations 2, 8) with few cells in the anergic subset (population 4) (Figure 4A). In addition, we can analyze the differences in surface marker expression of insulin, tetanus, and non-binding B cells by heat mapping, as discussed above (Figure 4B).

4. Discussion

Here we demonstrate that enrichment and characterization of antigen-binding B cells can be accomplished using magnetic nanoparticle adsorbents in conjunction with mass cytometry. Moreover, we show that simultaneous identification and analysis of more than one type of antigen-binding B cell is possible within the same sample. We believe this method will greatly inform our understanding of the phenotype and function of the pertinent antigen-reactive B cells during the course of the disease, such as in autoimmunity or cancer, as well as in infection, such as SARS-CoV2. The amount of information that can be gleaned from studying antigen-reactive B cells using mass cytometry data can lead to novel biomarker discoveries that can be used to predict and track the progression of disease and treatment outcomes.

While this method has its advantages over other techniques used to study antigen-reactive B cells, such as the ability to analyze many more parameters in one sample than one can achieve using flow cytometry and without the need for compensation or burden of possible autofluorescence, it does come with its own limitations. As discussed above, the low throughput of mass cytometry typically results in fewer cell events compared to flow cytometry, when starting from similar total cell numbers. One way to overcome this limitation is to start with more cells than you typically would for flow cytometry prior to enrichment. In addition, preliminary studies in our own lab have shown that the addition of “filler” cells labeled with a unique metal labeled anti-CD45 antibody mixed into the final enriched cell population can increase the number of enriched cells recovered for analysis.

Another limitation of this protocol is the limited availability of cleavable beads. Miltenyi Biotech currently offers anti-biotin, anti-FITC, anti-APC, and anti-PE cleavable beads. Due to the large size of APC and PE (105 kD and 250 kD, respectively), we prefer not to label our antigens with these fluorophores, since they potentially contain many antigenic epitopes

that could result in increased enrichment of fluorophore-reactive B cells, as previously described [26]. Hence, the use of biotin and FITC, which are much smaller in size (0.244 kD and 0.389 kD, respectively), to label antigens of interest limits the number of antigens that can be concurrently enriched for. Ideally, one could just directly label an antigen with a metal isotope and avoid the use of secondary antibodies for detection, which may be possible depending on the antigen of interest and immune status of the individual. However, from our experience, detection of antigen-reactive B cells from both autoimmune subjects and recently vaccinated individuals requires prior enrichment. In addition, we find the addition of a secondary antibody enhances the signal generated, allowing for better discrimination of binding from non-binding B cells.

Other general limitations of studying B cells using mass cytometry include (1) the lack of ability to study the repertoire, which is currently best accomplished using single-cell sequencing, (2) the inability to determine the relevant affinity of the BCR for its antigen, which would require knowledge of the variable region sequences, generation of recombinant antibodies, and testing their affinity for their antigen using surface plasmon resonance, and (3) the destruction of the cells in the process, which prevents the ability to conduct downstream functional or in vivo studies. While no method to study antigen-reactive B cells has proven to be without its faults, once detection has been optimized using flow cytometry, as previously described [10], this method is quick, relatively simple, and results in reproducible high dimensional data that can be used to deeply probe the immune system on an antigen-specific level.

Acknowledgments:

I would like to thank John Cambier for his careful review of the manuscript and his financial contribution.

Funding:

This research was funded by the University of Colorado School of Medicine Human Immunology & Immunotherapy Initiative (HI³), NIH K01 OD028759 (MJS), NIH DP3 DK110845 (Cambier), and NIH P30 DK116073 (Sussel).

References

1. Boonyaratanakornkit J; Taylor JJ Techniques to Study Antigen-Specific B Cell Responses. *Front. Immunol* 2019, 10, 1694. [PubMed: 31396218]
2. Haas W; Schrader JW; Szenberg A A new, simple method for the preparation of lymphocytes bearing specific receptors. *Eur. J. Immunol* 1974, 4, 565–570. [PubMed: 4137510]
3. De Wildt RM; Steenbakkers PG; Pennings AH; Hoogen FHVD; van Venrooij WJ; Hoet RM A new method for the analysis and production of monoclonal antibody fragments originating from single human B cells. *J. Immunol. Methods* 1997, 207, 61–67. [PubMed: 9328587]
4. Egeland T; Hovdenes A; Lea T; Egeland T; Hovdenes A; Lea T Positive Selection of Antigen-Specific B Lymphocytes by Means of Immunomagnetic Particles. *Scand. J. Immunol* 1988, 27, 439–444. [PubMed: 2834817]
5. Snow EC; Noelle RJ; Uhr JW; Vitetta ES Activation of antigen-enriched B cells. II. Role of linked recognition in B cell proliferation to thymus-dependent antigens. *J. Immunol* 1983, 130, 614–618. [PubMed: 6600245]
6. Pinder CL; Kratochvil S; Cizmeci D; Muir L; Guo Y; Shattock RJ; McKay PF Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry-Based Ig Capture Assay. *J. Immunol* 2017, 199, 4180–4188. [PubMed: 29118244]

7. Blanchard-Rohner G; Galli G; Clutterbuck EA; Pollard AJ Comparison of a limiting dilution assay and ELISpot for detection of memory B-cells before and after immunisation with a protein-polysaccharide conjugate vaccine in children. *J. Immunol. Methods* 2010, 358, 46–55. [PubMed: 20361969]
8. Doucett VP; Gerhard W; Owler K; Curry D; Brown L; Baumgarth N Enumeration and characterization of virus-specific B cells by multicolor flow cytometry. *J. Immunol. Methods* 2005, 303, 40–52. [PubMed: 16045923]
9. Saletti G; Çuburu N; Yang JS; Dey A; Czerkinsky C Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. *Nat. Protoc* 2013, 8, 1073–1087. [PubMed: 23660756]
10. Smith MJ; Packard TA; O'Neill SK; Hinman RM; Rihaneck M; Gottlieb PA; Cambier JC Detection and Enrichment of Rare Antigen-specific B Cells for Analysis of Phenotype and Function. *J. Vis. Exp* 2017.
11. Smith MJ; Hinman RM; Getahun A; Kim S; Packard TA; Cambier JC Silencing of high-affinity insulin-reactive B lymphocytes by anergy and impact of the NOD genetic background in mice. *Diabetologia* 2018, 61, 2621–2632. [PubMed: 30255377]
12. Smith MJ; Packard TA; O'Neill SK; Dunand CJH; Huang M; Fitzgerald-Miller L; Stowell D; Hinman RM; Wilson PC; Gottlieb PA; et al. Loss of Anergic B Cells in Prediabetic and New-Onset Type 1 Diabetic Patients. *Diabetes* 2014, 64, 1703–1712. [PubMed: 25524915]
13. Smith MJ; Rihaneck M; Wasserfall C; Mathews CE; Atkinson MA; Gottlieb PA; Cambier JC Loss of B-Cell Anergy in Type 1 Diabetes Is Associated With High-Risk HLA and Non-HLA Disease Susceptibility Alleles. *Diabetes* 2018, 67, 697–703. [PubMed: 29343548]
14. Smith MJ; Rihaneck M; Coleman BM; Gottlieb PA; Sarapura VD; Cambier JC Activation of thyroid antigen-reactive B cells in recent onset autoimmune thyroid disease patients. *J. Autoimmun* 2018, 89, 82–89. [PubMed: 29233566]
15. Leipold MD; Newell E; Maecker HT Multiparameter Phenotyping of Human PBMCs Using Mass Cytometry. *Methods Mol. Biol* 2015, 1343, 81–95. [PubMed: 26420710]
16. Newell E; Sigal N; Bendall SC; Nolan GP; Davis MM Cytometry by Time-of-Flight Shows Combinatorial Cytokine Expression and Virus-Specific Cell Niches within a Continuum of CD8+ T Cell Phenotypes. *Immunity* 2012, 36, 142–152. [PubMed: 22265676]
17. Gadalla R; Noamani B; MacLeod BL; Dickson RJ; Guo M; Xu W; Lukhele S; Elsaesser HJ; Razak ARA; Hirano N; et al. Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. *Front. Oncol* 2019, 9, 415. [PubMed: 31165047]
18. Lin D; Maecker HT Mass Cytometry Assays for Antigen-Specific T Cells Using CyTOF. *Adv. Struct. Saf. Stud* 2017, 1678, 37–47.
19. Newell EW; Sigal N; Nair N; Kidd BA; Greenberg HB; Davis MM Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. *Nat. Biotechnol* 2013, 31, 623–629. [PubMed: 23748502]
20. Wiedeman A; Muir VS; Rosasco MG; DeBerg HA; Presnell S; Haas B; Dufort MJ; Speake C; Greenbaum CJ; Serti E; et al. Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression. *J. Clin. Investig* 2019, 130, 480–490.
21. Fienberg HG; Simonds EF; Fantl WJ; Nolan GP; Bodenmiller B A platinum-based covalent viability reagent for single-cell mass cytometry. *Cytom. Part A* 2012, 81, 467–475.
22. Leipold MD; Maecker HT Mass Cytometry: Protocol for Daily Tuning and Running Cell Samples on a CyTOF Mass Cytometer. *J. Vis. Exp* 2012, 2012, e4398.
23. Kimball AK; Oko LM; Bullock BL; Nemenoff RA; Van Dyk LF; Clambey ET A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. *J. Immunol* 2018, 200, 3–22. [PubMed: 29255085]
24. Weber LM; Robinson MD Comparison of clustering methods for high-dimensional single-cell flow and mass cytometry data. *Cytom. Part A* 2016, 89, 1084–1096.
25. Liu X; Song W; Wong BY; Zhang T; Yu S; Lin GN; Ding X A comparison framework and guideline of clustering methods for mass cytometry data. *Genome Biol.* 2019, 20, 1–18. [PubMed: 30606230]

26. Pape KA; Taylor JJ; Maul R; Gearhart PJ; Jenkins MK Different B Cell Populations Mediate Early and Late Memory During an Endogenous Immune Response. *Science* 2011, 331, 1203–1207. [PubMed: 21310965]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1.

Schematic for magnetic enrichment of antigen-reactive B cells. 1. Human PBMCs are incubated with properly titrated amounts of biotin and FITC-labeled antigens. Cells are then incubated with a combination of cleavable anti-biotin and anti-FITC magnetic beads. 2. Washed cells are then added to a magnetic column and separated into depleted and enriched fractions. 3. Magnetic microbeads are cleaved off and washed away. 4. Cells are then incubated with an antibody cocktail containing various metal labeled antibodies. 5. Cells are analyzed on a mass cytometer. 6. Data analysis is performed using a combination of manual gating and dimensionality reduction and clustering algorithms.




Figure 2.

Representative comparison of enrichment of insulin and tetanus-binding B cells using flow cytometry and mass cytometry shows similar binding cell frequencies. Approximately 60 million PBMCs were collected from a single human donor, split in half, with each half enriched for insulin and tetanus-binding B cells as described in this protocol. **(A)** Representative binding of insulin and tetanus-binding B cells of depleted and enriched fractions using flow cytometry. **(B)** Representative binding of insulin and tetanus-binding B cells using mass cytometry. For the flow cytometry sample, the addition of fluorescently labeled antibodies (BV421 anti-CD19 and PerCP anti-CD3) and Streptavidin-AlexaFluor647 to detect biotinylated insulin bound to the BCR were incubated with the cells in place of


metal-labeled antibodies and secondaries. Depleted fractions are negatively enriched cells and enriched fractions are positively enriched cells. Data were analyzed using CellEngine.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Figure 4.**

Representative UMAP projections of various B cell subpopulations within the insulin, tetanus, and non-binding B cells demonstrate unique B cell compositions within each antigen-binding B cell subset. **(A)** Insulin-binding B cells can be found in all major B cell subpopulations, with increased frequency in the transitional and naïve (CD27⁻) subpopulations (populations 1, 3, 4, and 6). Tetanus-binding B cells are more enriched in the memory subpopulations (populations 2, 8) with few cells in the anergic subset (population 4). UMAP projections were generated using the unsupervised clustering algorithm, PhenoGraph, using the following markers: CD27, CD38, CD10, IgM, IgD, IgG, CXCR5, CD11c, and CD86. Antigen-binding populations were manually gated. **(B)** Representative heatmap of expression of various cell surface markers expressed on insulin, tetanus, and non-binding B cells. Colors represent raw mean metal intensities (MMI). Heatmap was generated using CellEngine.

Table 1.

Materials.

Name:	Company:	Catalog Number:	Comments:
LS Columns	Miltenyi Biotech	130-042-401	
Anti-Biotin Multi-sort Kit	Miltenyi Biotech	130-091-256	
Anti-FITC Multi-sort Kit	Miltenyi Biotech	130-058-701	
MACS manual separators	Miltenyi Biotech	Variable	
FcR Blocking Reagent human	Miltenyi Biotech	130-059-901	
Tetanus-toxoid	Colorado Serum Company		Unadjuvanted with no carrier proteins present
Human Insulin Biotinylated	Eagle Biosciences	INS30-G100	
PBS without calcium and magnesium			No contact with autoclaved bottles or beakers or dish soap
Ficoll-Paque PLUS	VWR International	95021-205	
Pierce™ FITC Antibody Labeling Kit	ThermoFisher Scientific	53027	
Pierce™ 16% Formaldehyde (w/v), Methanol-free	ThermoFisher Scientific	28908	Dilute to 1.6% with CSM.
Whole blood in heparinized collection tubes			We typically use at least 30 mL of whole blood to enrich our cells of interest
Cell Staining Media (CSM) (PBS + 0.5% BSA + 2 mM EDTA)			No contact with autoclaved bottles or beakers or dish soap
50 mL conical Tubes			
15 mL conical Tubes			
1.5 mL Eppendorf tubes			
MAXPAR-labeled antibodies of interest			
160Gd-anti-FITC antibody	Fluidigm	3160011B	
170Er-anti-biotin antibody	Fluidigm	3170003B	
Cisplatin live/dead	Fluidigm	201195	Stock at 25 mM
DNA Intercalator	Fluidigm	201192B	500 uM stock

Table 2.

Antibody panel.

Metal Isotopes:	Specificity:	Clone:	Vendor:
113Cd	CD45	HI30	Fluidigm
115In	CD3	HIT3a	Biolegend
141Pr	CD22	HIB22	Biolegend
142Nd	CD19	HIB19	Fluidigm
143Nd	CD5	UCHT2	Fluidigm
144Nd	CD69	FN50	Fluidigm
145Nd	CD95	DX2	Biolegend
146Nd	IgD	IA6-2	Fluidigm
147Sm	CD20	2H7	Fluidigm
148Nd	CD38	HIT2	Biolegend
149Sm	CD24	ML5	Biolegend
150Nd	CD86	IT2.2	Fluidigm
151Eu	HLA-DR	G46-6	Fluidigm
152Sm	CD36	5-271	Fluidigm
153Eu	CD8	SK1	Biolegend
154Sm	CD40	5C3	Biolegend
155Gd	CD27	L128	Fluidigm
156Gd	CXCR3	G025H7	Fluidigm
158Gd	CD10	HI10a	Fluidigm
159Tb	IgKappa	MHK-49	Biolegend
160Gd	Anti-FITC	FIT-22	Fluidigm
161Dy	CD80	2D10.4	Fluidigm
162Dy	CD11c	Bu15	Fluidigm
163Dy	CD72	3F3	Biolegend
164Dy	CD71	CY1G4	Biolegend
165Ho	CXCR5	J252D4	Biolegend
166Er	CD23	B3B4	Biolegend
167Er	IgLambda	1-155-2	Biolegend
168Er	CD138	DL-101	Fluidigm
169Tm	IgG	G18-145	BD Pharmingen
170Er	Anti-biotin	1D4-C5	Fluidigm
171Yb	PD-L1	29E.2A3	Biolegend
172Yb	IgM	MHM-88	Fluidigm
173Yb	CD21	Bu32	Biolegend
174Yb	CD4	SK3	Fluidigm
175Lu	CCR4	L291H4	Fluidigm
176Yb	PD-1	EH12.2H7	Biolegend

Metal Isotopes:	Specificity:	Clone:	Vendor:
191Ir	Intercalator		Fluidigm
193Ir	Intercalator		Fluidigm
195Pt	Live-dead		Fluidigm

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript